Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-020832
Filing Date
2023-05-11
Accepted
2023-05-11 07:15:46
Documents
74
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tcrr-20230331.htm   iXBRL 10-Q 2994566
2 EX-2.2 tcrr-ex2_2.htm EX-2 31375
3 EX-31.1 tcrr-ex31_1.htm EX-31 20490
4 EX-31.2 tcrr-ex31_2.htm EX-31 18814
5 EX-32.1 tcrr-ex32_1.htm EX-32 16515
6 GRAPHIC img16963646_0.jpg GRAPHIC 35409
  Complete submission text file 0000950170-23-020832.txt   10331297

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tcrr-20230331_pre.xml EX-101.PRE 379096
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tcrr-20230331.xsd EX-101.SCH 60121
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tcrr-20230331_cal.xml EX-101.CAL 54238
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tcrr-20230331_def.xml EX-101.DEF 214092
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tcrr-20230331_lab.xml EX-101.LAB 504967
68 EXTRACTED XBRL INSTANCE DOCUMENT tcrr-20230331_htm.xml XML 1919614
Mailing Address 100 BINNEY STREET CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET CAMBRIDGE MA 02142 617-949-5200
TCR2 THERAPEUTICS INC. (Filer) CIK: 0001750019 (see all company filings)

EIN.: 474152751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38811 | Film No.: 23908797
SIC: 2836 Biological Products, (No Diagnostic Substances)